WASHINGTON, Oct. 2 -- National Institutes of Health has issued a notice called: Prospective Grant of an Exclusive Patent License: Substituted Quinoline Analogs As Aldehyde Dehydrogenase 1A1 Inhibitors.
The notice was published in the Federal Register on Oct. 2 by Joni Rutter, Director, National Center for Advancing Translational Sciences, National Institutes of Health.
Summary: The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATIONsection of this notice to Stage One Immunothe...